<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment</title>
  </titleInfo>
  <name type="personal">
    <namePart>Paulina Chmiel</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Aleksandra SłOWIKOWSKA</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Łukasz Banaszek</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Anna Szumera-CIEćKIEWICZ</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>BARTłOMIEJ Szostakowski</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Mateusz J SPAłEK</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Tomasz Świtaj</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Piotr Rutkowski</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Anna M Czarnecka</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Review articles.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">xx</placeTerm>
    </place>
    <dateIssued encoding="marc">2024</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>1 online resource (1 article).</extent>
  </physicalDescription>
  <abstract>Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.</abstract>
  <note type="statement of responsibility">Paulina Chmiel; Aleksandra SłOWIKOWSKA; Łukasz Banaszek [and others].</note>
  <note>Publication type: Review article.</note>
  <note>Linked open-access copy: published version.</note>
  <note>Open access; no subscription required for the linked open-access version. Unrestricted online access star</note>
  <note xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution. See the linked licence for the applicable terms. https://creativecommons.org/licenses/by/4.0/</note>
  <note>In English.</note>
  <subject>
    <topic>Anaplastic Lymphoma Kinase (Alk)</topic>
  </subject>
  <subject>
    <topic>Inflammatory Myofibroblastic Tumor (Imt)</topic>
  </subject>
  <subject>
    <topic>Tyrosine Kinase Inhibitors (Tki)</topic>
  </subject>
  <subject>
    <topic>Epithelioid Inflammatory Myofibroblastic Sarcoma</topic>
  </subject>
  <subject>
    <topic>B. Sc. Medical Laboratory Science</topic>
  </subject>
  <subject>
    <topic>UMUN open access collection</topic>
  </subject>
  <subject>
    <topic>molecular diagnostics</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>Oncology research</title>
    </titleInfo>
    <identifier type="issn">0965-0407</identifier>
    <part>
      <text>Vol. 32, no. 7, (2024), pages/article 1141-1162</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://europepmc.org/articles/PMC11209743</identifier>
  <location>
    <url displayLabel="Read open-access publication">https://europepmc.org/articles/PMC11209743</url>
  </location>
  <accessCondition type="restrictionOnAccess">Open access; no subscription required for the linked open-access version.</accessCondition>
  <accessCondition type="useAndReproduction">Creative Commons Attribution. See the linked licence for the applicable terms.</accessCondition>
  <recordInfo>
    <recordContentSource authority="marcorg">local</recordContentSource>
    <recordCreationDate encoding="marc">261005</recordCreationDate>
    <recordChangeDate encoding="iso8601">20261005174906.0</recordChangeDate>
    <recordIdentifier source="local">UMUN-OA-20261005-MLS-059</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
